Clinical Trials Logo

Recurrent Vulvovaginal Candidiasis clinical trials

View clinical trials related to Recurrent Vulvovaginal Candidiasis.

Filter by:
  • None
  • Page 1

NCT ID: NCT02267382 Active, not recruiting - Clinical trials for Recurrent Vulvovaginal Candidiasis

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Start date: February 2015
Phase: Phase 2
Study type: Interventional

VT-1161 is a novel, oral inhibitor of fungal lanosterol demethylase (CYP51). In vitro and in vivo pharmacology studies have demonstrated that VT-1161 is highly active against Candida albicans and also non-albicans Candida species that cause vulvovaginal candidiasis. VT-1161 is highly selective for fungal CYP51, and data suggests that it may avoid the side-effect profile that limits the use of commonly prescribed antifungal agents for the treatment of recurrent yeast infections.

NCT ID: NCT01067131 Completed - Clinical trials for Recurrent Vulvovaginal Candidiasis

Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection

Start date: March 2010
Phase: Phase 1
Study type: Interventional

Pevion Biotech develops a state-of-the-art vaccine against recurrent vulvovaginal candidiasis (RVVC) caused by the pathogenic form of Candida albicans especially in pre-menopausal women of childbearing age with a history of recurrent vulvovaginal candidiasis. This study is designed to evaluate the safety and tolerability of the vaccine, administered by two different routes (intramuscular and intravaginal) as primary endpoint. Immunogenicity will be evaluated as secondary endpoint.